Advertisement

Archives of Osteoporosis

, 14:16 | Cite as

Glucocorticoid-induced osteoporosis preventive care in rheumatology patients

  • G. Koller
  • S. Katz
  • T. L. Charrois
  • C. YeEmail author
Original Article

Abstract

Summary

Glucocorticoid-induced osteoporosis (GIOP) is common in patients prescribed with long-term glucocorticoids. Guidelines suggest patients receiving moderate-dose glucocorticoid therapy receive GIOP preventive care. Previous studies have shown preventive care rates are not optimal. We look at GIOP preventive care rates in rheumatology patients and predictors of various components of care.

Purpose

Glucocorticoid-induced osteoporosis (GIOP) is a common concern in patients prescribed with long-term glucocorticoids. Studies have shown GIOP preventive care is not provided optimally in the general population; however, little is published on GIOP preventive care among patients with rheumatic disease. The objective of this study is to determine the proportion of rheumatology patients who received GIOP preventive care.

Methods

A population-based retrospective quality assurance study of adults seen at the University of Alberta Rheumatology Clinic was performed using the electronic outpatient medical record. Records of adult patients prescribed with prednisone from January 1st to December 31st, 2016 by a rheumatologist were initially included for review. Those who had been prescribed ≥ 7.5 mg/day for ≥ 3 months were assessed for concurrent GIOP preventive care.

Results

A total of 745 discreet courses of prednisone were prescribed in 433 patients with 113 meeting the above inclusion criteria. Following the prednisone prescription, 79% were taking vitamin D, 86% were taking calcium, and 50% were prescribed with osteoporosis pharmacotherapy. Twenty-five percent of patients had DXA imaging ordered by the rheumatologist within the first 6 months; of these, 86% of patients completed the DXA.

Conclusions

Overall, our study shows that patients under the care of rheumatologists receive better GIOP preventative care than previously reported care in the general population. However, there is still room for improvement. In particular, men, younger patients, and rural patients seem to be at the most at risk of not receiving optimal GIOP prevention.

Keywords

Glucocorticoid Steroid Bisphosphonate Osteoporosis Rheumatologist 

Notes

Acknowledgements

Authors’ roles: Study design: GK, SK, TLC, and CY. Study conduct: GK and CY. Data collection: GK and CY. Data analysis: GK, TLC, and CY. Data interpretation: GK, SK, TLC, and CY. Drafting manuscript: GK and CY. Revising manuscript: GK, SK, TLC, and CY. Revising manuscript content: GK, SK, TLC, and CY. Approving final version of manuscript: GK, SK, TLC, and CY. GK takes responsibility for the integrity of the data analysis.

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27:807–813PubMedGoogle Scholar
  2. 2.
    Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, Gaudin P, Jorgensen C, Prades BP, Wendling D, Maillefert JF (2014) Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatol (United Kingdom) 54:672–677.  https://doi.org/10.1093/rheumatology/keu339 CrossRefGoogle Scholar
  3. 3.
    Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, le Bars M (2016) Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open 2:e000228.  https://doi.org/10.1136/rmdopen-2015-000228 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 365:62–70.  https://doi.org/10.1056/NEJMcp1012926 CrossRefPubMedGoogle Scholar
  5. 5.
    LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51CrossRefGoogle Scholar
  6. 6.
    Van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229.  https://doi.org/10.1002/art.11283 CrossRefPubMedGoogle Scholar
  7. 7.
    Van Staa TP, Leufkens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787 . doi:  https://doi.org/10.1007/s001980200108
  8. 8.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (London, England) 353:878–882.  https://doi.org/10.1016/S0140-6736(98)09075-8 CrossRefGoogle Scholar
  9. 9.
    Chrischilles E, Shireman T, Wallace R (1994) Costs and health effects of osteoporotic fractures. Bone 15:377–386.  https://doi.org/10.1016/8756-3282(94)90813-3 CrossRefPubMedGoogle Scholar
  10. 10.
    Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet (London, England) 359:1761–1767.  https://doi.org/10.1016/S0140-6736(02)08657-9 CrossRefGoogle Scholar
  11. 11.
    Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182:1864–1873.  https://doi.org/10.1503/cmaj.100771 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276.  https://doi.org/10.1007/s00198-012-1958-1 CrossRefPubMedGoogle Scholar
  13. 13.
    Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095–1110.  https://doi.org/10.1002/acr.23279 CrossRefGoogle Scholar
  14. 14.
    Majumdar SR, Lix LM, Yogendran M, Morin SN, Metge CJ, Leslie WD (2012) Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab 97:1236–1242.  https://doi.org/10.1210/jc.2011-2645 CrossRefPubMedGoogle Scholar
  15. 15.
    Trijau S, De Lamotte G, Pradel V et al (2016) Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database. RMD Open 2:1–7.  https://doi.org/10.1136/rmdopen-2016-000249 CrossRefGoogle Scholar
  16. 16.
    Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM (2014) Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol 21:e486–e504PubMedGoogle Scholar
  17. 17.
    Canada Post Addressing Guidelines. https://www.canadapost.ca/tools/pg/manual/PGaddress-e.pdf. Accessed 16 May 2018
  18. 18.
    Overman RA, Toliver JC, Yeh J-Y, Gourlay ML, Deal CL (2014) United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 66:1644–1652.  https://doi.org/10.1002/acr.22346 CrossRefGoogle Scholar
  19. 19.
    Ozen G, Kamen DL, Mikuls TR, England BR, Wolfe F, Michaud K (2017) Trends and determinants of osteoporosis treatment and screening in patients with rheumatoid arthritis compared to osteoarthritis. Arthritis Care Res (Hoboken) 70:713–723.  https://doi.org/10.1002/acr.23331 CrossRefGoogle Scholar
  20. 20.
    Watt J, Thompson A, Le Riche N, Pope J (2014) There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. Joint Bone Spine 81:347–351.  https://doi.org/10.1016/j.jbspin.2014.02.001 CrossRefPubMedGoogle Scholar
  21. 21.
    Cosman F (2018) Long-term treatment strategies for postmenopausal osteoporosis. Curr Opin Rheumatol 1:420–426.  https://doi.org/10.1097/BOR.0000000000000509 CrossRefGoogle Scholar
  22. 22.
    Cotts KG, Cifu AS (2018) Treatment of osteoporosis. JAMA 319:1040–1041.  https://doi.org/10.1001/jama.2017.21995 CrossRefPubMedGoogle Scholar
  23. 23.
    Watts NB (2018) Postmenopausal osteoporosis: a clinical review. J Women’s Heal jwh.2017.6706 . doi:  https://doi.org/10.1089/jwh.2017.6706

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of MedicineUniversity of AlbertaEdmontonCanada
  2. 2.Department of Medicine, Division of RheumatologyUniversity of AlbertaEdmontonCanada
  3. 3.Faculty of Pharmacy and Pharmaceutical SciencesUniversity of AlbertaEdmontonCanada

Personalised recommendations